117 related articles for article (PubMed ID: 35985446)
1. Potential role of CXCR4 in trastuzumab resistance in breast cancer patients.
Kotb RM; Ibrahim SS; Mostafa OM; Shahin NN
Biochim Biophys Acta Mol Basis Dis; 2022 Nov; 1868(11):166520. PubMed ID: 35985446
[TBL] [Abstract][Full Text] [Related]
2. Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.
Liu S; Xie SM; Liu W; Gagea M; Hanker AB; Nguyen N; Singareeka Raghavendra A; Yang-Kolodji G; Chu F; Neelapu SS; Marchese A; Hanash S; Zimmermann J; Arteaga CL; Tripathy D
Breast Cancer Res; 2023 Jun; 25(1):62. PubMed ID: 37280713
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
4. Exosomal Linc00969 induces trastuzumab resistance in breast cancer by increasing HER-2 protein expression and mRNA stability by binding to HUR.
Liu C; Lu C; Yixi L; Hong J; Dong F; Ruan S; Hu T; Zhao X
Breast Cancer Res; 2023 Oct; 25(1):124. PubMed ID: 37848981
[TBL] [Abstract][Full Text] [Related]
5. Heregulin/ErbB3 Signaling Enhances CXCR4-Driven Rac1 Activation and Breast Cancer Cell Motility via Hypoxia-Inducible Factor 1α.
Lopez-Haber C; Barrio-Real L; Casado-Medrano V; Kazanietz MG
Mol Cell Biol; 2016 Aug; 36(15):2011-26. PubMed ID: 27185877
[TBL] [Abstract][Full Text] [Related]
6. ENTREP/FAM189A2 encodes a new ITCH ubiquitin ligase activator that is downregulated in breast cancer.
Tsunoda T; Riku M; Yamada N; Tsuchiya H; Tomita T; Suzuki M; Kizuki M; Inoko A; Ito H; Murotani K; Murakami H; Saeki Y; Kasai K
EMBO Rep; 2022 Feb; 23(2):e51182. PubMed ID: 34927784
[TBL] [Abstract][Full Text] [Related]
7. Activation of STAT3/HIF-1α/Hes-1 axis promotes trastuzumab resistance in HER2-overexpressing breast cancer cells via down-regulation of PTEN.
Aghazadeh S; Yazdanparast R
Biochim Biophys Acta Gen Subj; 2017 Aug; 1861(8):1970-1980. PubMed ID: 28499822
[TBL] [Abstract][Full Text] [Related]
8. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
[TBL] [Abstract][Full Text] [Related]
9. Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.
Liu S; Xie SM; Liu W; Gagea M; Hanker AB; Nguyen N; Raghavendra AS; Yang-Kolodji G; Chu F; Neelapu SS; Hanash S; Zimmermann J; Arteaga CL; Tripathy D
Res Sq; 2023 Feb; ():. PubMed ID: 36824840
[No Abstract] [Full Text] [Related]
10. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL.
Staller P; Sulitkova J; Lisztwan J; Moch H; Oakeley EJ; Krek W
Nature; 2003 Sep; 425(6955):307-11. PubMed ID: 13679920
[TBL] [Abstract][Full Text] [Related]
11. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
14. Involvement of Numb-mediated HIF-1α inhibition in anti-proliferative effect of PNA-antimiR-182 in trastuzumab-sensitive and -resistant SKBR3 cells.
Sajadimajd S; Yazdanparast R; Akram S
Tumour Biol; 2016 Apr; 37(4):5413-26. PubMed ID: 26563369
[TBL] [Abstract][Full Text] [Related]
15. Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression.
Liu J; Zhang C; Zhao Y; Yue X; Wu H; Huang S; Chen J; Tomsky K; Xie H; Khella CA; Gatza ML; Xia D; Gao J; White E; Haffty BG; Hu W; Feng Z
Nat Commun; 2017 Nov; 8(1):1823. PubMed ID: 29180628
[TBL] [Abstract][Full Text] [Related]
16. Regulation of CXCR4 gene expression in breast cancer cells under diverse stress conditions.
Andreou K; Rajendran R; Krstic-Demonacos M; Demonacos C
Int J Oncol; 2012 Dec; 41(6):2253-9. PubMed ID: 23023398
[TBL] [Abstract][Full Text] [Related]
17. MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6.
Lu X; Ma J; Chu J; Shao Q; Zhang Y; Lu G; Li J; Huang X; Li W; Li Y; Ling Y; Zhao T
Cell Physiol Biochem; 2017; 44(6):2346-2356. PubMed ID: 29258115
[TBL] [Abstract][Full Text] [Related]
18. Posttranscriptional control of the chemokine receptor CXCR4 expression in cancer cells.
Al-Souhibani N; Al-Ghamdi M; Al-Ahmadi W; Khabar KS
Carcinogenesis; 2014 Sep; 35(9):1983-92. PubMed ID: 24692066
[TBL] [Abstract][Full Text] [Related]
19. PKCα Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance.
Pandya K; Wyatt D; Gallagher B; Shah D; Baker A; Bloodworth J; Zlobin A; Pannuti A; Green A; Ellis IO; Filipovic A; Sagert J; Rana A; Albain KS; Miele L; Denning MF; Osipo C
Clin Cancer Res; 2016 Jan; 22(1):175-86. PubMed ID: 26350262
[TBL] [Abstract][Full Text] [Related]
20. The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene.
Tormo E; Adam-Artigues A; Ballester S; Pineda B; Zazo S; González-Alonso P; Albanell J; Rovira A; Rojo F; Lluch A; Eroles P
Sci Rep; 2017 Jan; 7():41309. PubMed ID: 28120942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]